Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023.

That analysis indicated an increasing trend in ADT combined with ARPI over time; nonetheless, ADT monotherapy was predominantly used to treat patients in most studies. 20 Potential reasons for clinical inertia regarding persistent ADT monotherapy use include clinical preference, health system factors, or access-related reasons. 20 Characteristics such as young age, good performance status, few comorbidities, high disease burden (indicated by assessment of prognostic risk, tumor volume, and/or metastatic spread), and care provision by oncologists have been identified as drivers of use of ADT combination therapy.

also in 63,971 other papers